An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Volanesorsen (Primary)
- Indications Hyperlipoproteinaemia type I
- Focus Therapeutic Use
- Acronyms The Approach Open Label Study
- Sponsors Ionis Pharmaceuticals
- 04 Jan 2017 Time frame of primary endpoint has been changed from 52 Weeks to 117 Weeks.
- 04 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2018.
- 04 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2018.